Trial Profile
A Phase III, Open-Label, Randomized Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 29 Dec 2023
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Bevacizumab (Primary) ; Sorafenib
- Indications Liver cancer
- Focus Registrational; Therapeutic Use
- Acronyms IMbrave150
- Sponsors Chugai Pharmaceutical; Roche; Roche Farma
- 29 Dec 2023 this trial has been suspended in Italy.
- 24 Oct 2023 Results (n=208) of the study evaluating the clinical and immunological implications of thyroid dysfunction in unresectable hepatocellular carcinoma (HCC) patients treated with atezolizumab and bevacizumab (Ate/Bev) presented at the 48th European Society for Medical Oncology Congress.
- 13 Aug 2023 This trial has been discontinued in Spain (Date of the global end of the trial: 17-Nov-2022), according to the European Clinical Trials Database record.